Takeda Licenses F-star’s Immuno-oncology Bispecific Antibody Technology
By Lucy Haggerty
Pharma Deals Review: Vol 2022 Issue 7 (Table of Contents)
Published: 25 Jul-2022
DOI: 10.3833/pdr.v2022.i7.2707 ISSN: 1756-7874
Section: Licensing
Fulltext:
Abstract
In order to boost its T-cell engager portfolio, Takeda has entered into a license agreement with F-star Therapeutics to research, develop and commercialise a bispecific antibody against an immuno-oncology target...
This page is available to subscribers only.
Not a subscriber? Join here
Already Registered? Please login using the top left purple box.
Copyright: © IQVIA 2018
RSS